HomeLatest NewsCovid-19FDA authorizes Remdesivir for Certain Non-Hospitalized Patients, New At-Home Test for COVID-19

FDA authorizes Remdesivir for Certain Non-Hospitalized Patients, New At-Home Test for COVID-19

The Food and Drug Administration Friday expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19. The agency also authorized emergency use of the drug for high-risk, non-hospitalized pediatric patients who weigh less than 88 but more than 8 pounds, including patients under age 12. The drug previously was limited to hospitalized patients. The expanded uses are based on results from a clinical trial that showed the drug reduced hospitalizations in high-risk, non-hospitalized patients. For more information, see the updated provider and patient fact sheets.

Last week the FDA issued an emergency use authorization for another over-the-counter COVID-19 test, MaximBio ClearDetect COVID-19 Antigen Home Test, that delivers results in 15 minutes.

Stay Connected

Unified Voice Newsletter

Events This Month


26sep11:00 am12:00 pmFall Prevention: Keeping our older patients Standing StrongSDAHO Webinar

26sep12:00 pm1:00 pmApprenticeships: Build Your Team and Strengthen the Aging Services Workforce

27sep12:00 pm1:00 pmAchieving Sustained Reduction in Blood Culture ContaminationAHA Webinar

27sepAll Day28SD Rural Health Equity SummitWest River AHEC

28sep12:00 pm1:30 pmGrievance and Complaints: Ensuring Hospitals Compliance with the CMS COPs, Joint Commission, DNV Standards and OCRSDAHO Webinar

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact